ππ‘ππ«π¦πππ² ππ§π ππ¨π’π¬π¨π§π¬ ππ¨ππ«π ππ§πππ«πππ€ππ¬ πππ«ππππ π’π πππ―π’ππ° ππ¨π« ππ₯π’π π§π¦ππ§π π°π’ππ‘ ππππ’π¨π§ππ₯ ππππ₯ππ‘ ππ¨ππ₯π¬, 6th November 2023
Mombasa, KENYA – The Pharmacy and Poisons Board (PPB) is currently immersed in a vital strategic review, with a strong emphasis on result-oriented management and alignment with the government’s Bottom-up Economic agenda (BETA) and Universal Health Coverage. This week, the PPB’s Board of Directors and management have convened in Mombasa to ensure their 2020-2025 strategic plan harmonizes with national objectives.
Dr. Charles Githinji, Chairman of the PPB, has emphasized several key priorities, including achieving WHO Maturity Level 3, implementing result-based management, addressing issues related to unregistered outlets, resource mobilization, and promoting teamwork. These priorities are aimed at aligning the PPB with national healthcare objectives.
Additionally, Dr. F.M. Siyoi, the CEO of the PPB, has stressed the need for change and has provided assurance that the management team is well-prepared for this transformative journey. The pharma sector’s vital role in ensuring the quality, safety, and efficacy of healthcare products is paramount to the nation’s health and overall well-being.
